ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Valuation Check After New EMA Support For Dupixent And Acoziborole
Sanofi (ENXTPA:SAN) is back in focus after two fresh positive opinions from Europe’s medicines regulator on Dupixent for pediatric chronic spontaneous urticaria and Acoziborole Winthrop for sleeping sickness, spotlighting its late stage specialty portfolio.
See our latest analysis for Sanofi.
Sanofi’s latest Dupixent and Acoziborole milestones arrive as the shares trade at €82.2, with a 1 month share price return of 6.64% and a 1 day move of 1.63%. However, a 1 year total shareholder return...